版本:
中国

BRIEF-Immunovaccine says to initiate mid-stage trial of its blood cancer drug

May 16 Immunovaccine Inc

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug

* Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐